Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $31,437.68 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,503 shares of the business’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $12.56, for a total value of $31,437.68. Following the completion of the sale, the insider now owns 161,860 shares in the company, valued at $2,032,961.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 15th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $13.95, for a total value of $34,916.85.
• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.17, for a total transaction of $965,130.57.
• On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40.
• On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total value of $229,075.17.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $11.25 on Friday. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $17.16. The stock’s fifty day moving average is $13.97 and its 200 day moving average is $10.22.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $246.60 million for the quarter, compared to analyst estimates of $245.84 million. During the same quarter last year, the business posted ($0.05) EPS. The firm’s revenue for the quarter was up 47.4% on a year-over-year basis. On average, analysts predict that Hims & Hers Health, Inc. will post 0.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HIMS. FNY Investment Advisers LLC bought a new stake in shares of Hims & Hers Health during the fourth quarter worth $48,000. Belpointe Asset Management LLC acquired a new stake in shares of Hims & Hers Health during the third quarter valued at about $76,000. EMC Capital Management grew its holdings in shares of Hims & Hers Health by 80.0% during the third quarter. EMC Capital Management now owns 12,000 shares of the company’s stock worth $79,000 after purchasing an additional 5,332 shares during the last quarter. Certuity LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $109,000. Finally, Corton Capital Inc. acquired a new stake in Hims & Hers Health during the 3rd quarter worth approximately $122,000. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. SVB Leerink started coverage on shares of Hims & Hers Health in a research report on Monday, February 26th. They set a “market perform” rating and a $10.00 price target on the stock. Piper Sandler lifted their price target on Hims & Hers Health from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 27th. Truist Financial upped their price objective on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research note on Tuesday, February 27th. Tigress Financial lifted their target price on Hims & Hers Health from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 5th. Finally, Citigroup raised their price target on Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $14.85.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.